GlassScriptPhysician profile
William C Giles
NPI 1720029747
$946.63
in general payments reported to CMS, 2019-2025
14 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $41.44 · 2021: $128 · 2022: $166 · 2023: $314 · 2024: $132 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554 · Education: $56.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.42 |
| Education | $56.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $506.69 | 2020-2025 | |
| Genzyme Corporation | $143.87 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $56.01 | 2023 | Dupixent |
| Kerecis Limited | $33.15 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Novartis Pharmaceuticals Corporation | $28.21 | 2024 | |
| Acclarent, INC | $27.25 | 2023 | Trudi Nav Cable, Acclarent Aera |
| Alk-Abello, INC | $24.06 | 2021 | |
| Amgen INC. | $21.40 | 2025 | |
| Hikma Pharmaceuticals USA | $20.06 | 2023 | Ryaltris |
| Smith+Nephew, INC. | $19.99 | 2022 | |
| Aerin Medical INC. | $18.24 | 2022 | |
| Glaxosmithkline, LLC. | $18.20 | 2025 | Nucala |
| Integra Lifesciences Corporation | $16.97 | 2024 | Acclarent Aera |
| Medtronic USA, INC. | $12.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Giles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.